The FDA approved sofosbuvir-velpatasvir (Epclusa, Gilead), the first all-oral, pangenotypic, single-tablet regimen to treat adults with chronic hepatitis C virus (HCV) genotypes 1 to 6.
The drug is a fixed-dose combination tablet containing sofosbuvir (Sovaldi, Gilead), a drug approved in 2013, and velpatasvir, a new agent, and the first single-tablet regimen approved for patients with HCV genotypes 2 and 3, without the need for ribavirin (RBV).
Sofosbuvir-velpatasvir for 12